Overview

Doravirine Dose Optimisation in Pregnancy

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A randomised, open label, controlled PK standard of care vs doravirine plus 2 nucleoside reverse transcriptase inhibitors backbone in pregnant women initiating combination antiretroviral therapy in the second trimester of pregnancy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Liverpool
Collaborators:
Desmond Tutu Health Foundation
Liverpool School of Tropical Medicine
Treatments:
Dolutegravir